- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Zontivity
Synonyms :
vorapaxar
Class :
Antiplatelet ad protease- Activated Receptor-1 (PAR-1) Antagonist
Dosage Forms & Strengths
Tablet, Oral:
2.08 mg
Note: there is no monotherapy available with use of vorapaxar
may have an increased anticoagulant effect when combined with Enoxaparin
may have an increased anticoagulant effect when combined with Heparin
vorapaxar increases the toxicity of anticoagulants
vorapaxar increases the toxicity of anticoagulants
vorapaxar increases the toxicity of anticoagulants
vorapaxar increases the toxicity of anticoagulants
vorapaxar increases the toxicity of anticoagulants
vorapaxar: they may diminish the serum concentration of CYP3A4 Inducers
vorapaxar: they may diminish the serum concentration of CYP3A4 Inducers
vorapaxar: they may diminish the serum concentration of CYP3A4 Inducers
vorapaxar: they may diminish the serum concentration of CYP3A4 Inducers
vorapaxar: they may diminish the serum concentration of CYP3A4 Inducers
the effect of vorapaxar is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of vorapaxar
CYP3A4 inducers decrease the concentration of vorapaxar in serum
may enhance the toxic effect of anti-coagulants
Omega-3 Fatty Acids: they may increase the antiplatelet effect of antiplatelet agents
tenoxicam: they may increase the anticoagulant effect of Antiplatelet agents
probenecid: they may increase the anticoagulant effect of Antiplatelet agents
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may enhance the anticoagulant effect of thrombolytic agents
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
choline magnesium trisalicylate
may enhance the adverse effect of salicylates
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
choline magnesium trisalicylate
may increase the risk of adverse effects
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
It may enhance the risk of bleeding by affecting coagulation when combined with omega-3 carboxylic acids
when both drugs are combined, there may be an increased effect of other antiplatelet agents
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of antiplatelet agents
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may increase the antiplatelet effect of antiplatelet agents
May have an increasingly adverse effect when combined with Antiplatelet agents
May have an increased antiplatelet effect when combined with Antiplatelet agents
it increases the toxicity of antiplatelet agents
choline magnesium trisalicylate
antiplatelet agents increase the toxicity of salicylates
other antiplatelet agents increase the toxicity of ibritumomab tiuxetan
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may increase the toxic effect of anti-coagulants
may increase the anti-coagulant effect of Anti-coagulants
may increase the anticoagulant effect of Anticoagulants
anagrelide: they may increase the antiplatelet effect of antiplatelet agents
prostaglandin: they may increase the antiplatelet effect of antiplatelet agents
prostaglandin: they may increase the antiplatelet effect of antiplatelet agents
Vitamin B12: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
zanubrutinib: they may increase the antiplatelet effect of antiplatelet agents
dasabuvir: they may increase the anticoagulant effect antiplatelet agents
tipranavir: they may increase the antiplatelet effect of antiplatelet properties
may intensify the negative/harmful impact of caplacizumab
Frequency defined:
>10%
Hamorrhage
1% to 10%
Depression
Skin rash
Iron deficiency
Anemia
Retiopathy
<1%:
Diplopia hemorrhagic death
Intracranial hemorrhage
Pregnancy consideration: Not safe, risk of maternal bleeding and hemorrhage. It Falls under category D.
Lactation: vorapaxar can be excreted in breast milk. Not recommended during lactation.
Pregnancy category:
Patient information leaflet
Generic Name: Vorapaxar
Pronounced: vorapaxar
Why do we use vorapaxar?
Vorapaxar is used for the treatment of peripheral arterial disease in patients with a history of myocardial infarction.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
